Table 5.

Ongoing and recently completed GLP1-RA + insulin studies from Clinicaltrials.gov

Citation	Phase	Intervention	Background treatment	Estimated enrollment	Treatment duration	Primary outcome	Status	Est. Completion for primary outcome
NCT01191268	III	Dulaglutide QW + lispro*	± OAMs	837	52 weeks	ΔHbA1c at 26 weeks	Active	February 2012
		Glargine + lispro*
NCT00976391	III	Albiglutide QW + glargine	± OAMs	500	26 weeks	ΔHbA1c at 26 weeks	Completed	March 2011
		Lispro* + glargine
NCT01476475	II	Lixisenatide QD + Glargine	Metformin	310	24 weeks	ΔHbA1c at 24 weeks	Recruiting	December 2012
		Glargine
NCT00715624	III	Lixisenatide QD	Basal Insulin ± Metformin	450	24 weeks	ΔHbA1c at 24 weeks	Completed	February 2011
		Placebo
NCT00975286	III	Lixisenatide QD	Glargine + Metformin ± TZD	446	24 weeks	ΔHbA1c at 24 weeks	Completed	August 2011
		Placebo
NCT01336023	III	Liraglutide QD	OAMs	1660	26 weeks	ΔHbA1c at 26 weeks	Active	November 2012
		Degludec†
		Liraglutide QD + degludec†
NCT01392573	III	Degludec†	Metformin	382	26 weeks	ΔHbA1c at 26 weeks	Active	October 2012
		Liraglutide QD + Degludec†
NCT01505673	IV	Liraglutide QD	High dose insulin	80	6 months	ΔHbA1c at 2 and 6 months	Recruiting	June 2013
		Placebo
NCT00960661	III	Exenatide BID	Glargine Metformin ± SU	975	30 weeks	ΔHbA1c at 30 weeks	Recruiting	August 2012
		Lispro*
NCT01006889	IV	Exenatide BID	Detemir	24	6 months	Hepatic steatosis	Active	December 2009
NCT01140893	II/III	Exenatide BID	CSII	110	26 weeks	ΔHbA1c at 26 weeks	Recruiting	May 2012
		Placebo
NCT01076842	IV	Detemir	≥2 OAMs	75	24 weeks	ΔHbA1c at 24 weeks	Completed	April 2011
		Exenatide BID
		Detemir + exenatide BID

BID, twice daily; CSII, continuous subcutaneous insulin infusion; OAM, oral antihyperglycaemic medication; QD, once daily; QW, once weekly; SU, sulphonylurea; TZD, thiazolidinediones. Compiled from http://www.clinical trials.gov. Accessed 21 March 2012.

^*Insulin lispro, a rapid-acting insulin.

^†Insulin degludec, an long-acting insulin under development.